Clinical trials: Rivaroxaban
Thrombosis, Bleeding
Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
The goal of this retrospective clinical trial is to find out association antiplatelet and anticoagulant therapy with perioperative complications in non-cardiac vascular surgery in patients .
- Conditions
- Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure
- Trial name
- NCT07358416
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- Petrovsky National Research Centre of Surgery
Venous Thromboembolism, Haemorrhage
Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy
Study Objective: To assess the value of Rivaroxaban for the prevention of venous thromboembolism (VTE) after knee arthroscopy (KA) taking the placebo as standard of reference.
- Trial name
- ERIKA (NCT01629381)
- Testing
- Rivaroxaban
- Where
- 9 sites in Italy
- Volunteers
- 500 people
- Sponsor
- University of Padova
Portal Vein Thrombosis, Mesenteric Vein Thrombosis
Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study
Anticoagulant therapy is generally recommended for all patients presenting with acute symptomatic splanchnic vein thrombosis, starting with either low-molecular weight heparin (LMWH) or unfractionated heparin and continuing with…
- Conditions
- Portal Vein Thrombosis, Mesenteric Vein Thrombosis, Splenic Vein Thrombosis
- Trial name
- NCT02627053
- Testing
- rivaroxaban
- Where
- 4 sites in Canada, Italy
- Volunteers
- 100 people
- Sponsor
- Università degli Studi dell'Insubria
Bleeding
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
"This is a single-center, randomized, double-blind, and placebo-controlled trial designed to: 1) demonstrate the degree to which administered andexanet doses can reverse Factor Ten A (FXa)-inhibitor induced anticoagulation; and…
- Trial name
- NCT03310021
- Testing
- Andexanet alfa, Apixaban, Rivaroxaban
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Atrial Fibrillation
Italian Registry In the Setting of AF Ablation With Rivaroxaban (IRIS)
The aim of IRIS study is to observe the safety and efficacy of Rivaroxaban in subjects undergoing catheter ablation for atrial fibrillation (AF) in real-world clinical practice.
- Trial name
- IRIS (NCT04315974)
- Testing
- Rivaroxaban, Catheter ablation
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Dr Carlo Lavalle
Radial Artery Occlusion
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency.
- Trial name
- CAPITAL-RAPTOR (NCT03630055)
- Testing
- Rivaroxaban 15 MG Oral Tablet [Xarelto]
- Where
- 3 sites in United States, Canada
- Volunteers
- 930 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Covid19
Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment
The present study is designed for patients with mild COVID-19 phase, to demonstrate if there is a modification in the clinical evolution greater than or equal to 25% in their symptoms, implemented in two groups of patients under…
- Trial name
- NCT04673214
- Testing
- Azithromycin / Ivermectin / Ribaroxaban / Paracetamol, Azithromycin / Ribaroxaban / Paracetamol
- Where
- Mexico
- Volunteers
- 114 people
- Sponsor
- Gilberto Cruz Arteaga
Prophylaxis of Venous Thromboembolism
PK of Rivaroxaban in Bariatric Patients - Extension
Aim of this clinical Trial is the assessment of rivaroxaban PK/PD parameters in patients 6-8 months after bariatric surgery
- Trial name
- NCT02832947
- Testing
- Rivaroxaban 10 mg
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Hip Osteoarthritis, Blood Loss
Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).
- Trial name
- NCT02085824
- Testing
- Enoxaparin, rivaroxaban, dabigatran
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Centre of Postgraduate Medical Education
Atrial Fibrillation
Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
The purpose of this study is to evaluate the antiinflammatory effects of rivaroxaban compared with dabigatran in patients with atrial fibrillation.
- Trial name
- RIVAL-AF (NCT02331602)
- Testing
- Rivaroxaban, Dabigatran
- Where
- 16 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Yokohama City University Medical Center
Patient Engagement, Patient Satisfaction
Alexa, What is Eliquis and Xarelto?
The purpose of this study is to evaluate the effectiveness of providing patient medication education about Eliquis and Xarelto through an Amazon Alexa based voice recording.
- Trial name
- NCT04790773
- Testing
- Amazon Alexa based voice recording patient education
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Atrial Fibrillation
BAY59-7939 in Atrial Fibrillation Once Daily (OD)
This is an exploratory investigation of safety, pharmacokinetic (PK) and pharmacodynamic (PD) effects of BAY59-7939 with multiple oral doses of 10 mg, 15 mg and 20 mg once daily (od) in Japanese subjects with non-valvular atrial…
- Trial name
- NCT00973245
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), Warfarin
- Where
- 11 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Bayer
Healthy Participants
Bioequivalence Study of Rivaroxaban 2.5 mg Tablets Under Fasting and Fed Conditions
This completed study compared how the body absorbed a single 2.5 mg dose of a test rivaroxaban tablet and the reference product (Xarelto) in healthy adults.
- Trial name
- NCT07807488
- Testing
- Rivaroxaban 2.5 mg Test Tablet, Rivaroxaban 2.5 mg Reference Tablet
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Stroke, Atrial Fibrillation
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial fibrillation occurring…
- Trial name
- ASPIRE-AF (NCT03968393)
- Testing
- Non-vitamin K oral anticoagulant (NOAC)
- Where
- 105 sites in United States, Argentina and 16 more
- Volunteers
- 2,270 people
- Sponsor
- Population Health Research Institute
Atrial Fibrillation
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents
Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown their excellent safety and efficacy…
- Trial name
- NCT04250116
- Testing
- NOAC monotherapy, Dual antithrombotic therapy with NOAC and clopidogrel
- Where
- South Korea
- Volunteers
- 960 people
- Sponsor
- Yonsei University
Ischemic Stroke, Transient Ischemic Attack
Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
Rationale Acute ischemic stroke due to atrial fibrillation (AF) carries a high risk for early recurrence. In acute stage, guidelines recommend aspirin, but do not recommend anticoagulation due to the increased risk of…
- Trial name
- TripleAXEL (NCT02042534)
- Testing
- Rivaroxaban, Warfarin
- Where
- South Korea
- Volunteers
- 195 people
- Sponsor
- Asan Medical Center
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Pulmonary Embolism
Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in the treatment of pulmonary embolism (PE) and the prevention of the occurrence and the recurrence…
- Trial name
- NCT01516814
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Unfractionated heparin, Warfarin
- Where
- 31 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Bayer
Hemorrhage, Intracranial Hemorrhages
Restarting Anticoagulation After Traumatic Intracranial Hemorrhage
Primary Objective: To identify the optimal interval to restart oral anticoagulation after traumatic intracranial hemorrhage that will minimize thrombotic events and major bleeding by performing a response adaptive randomized…
- Conditions
- Hemorrhage, Intracranial Hemorrhages, Bleeding, Trauma
- Trial name
- Restart tICrH (NCT04229758)
- Testing
- Anticoagulants
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- University of Texas at Austin
Stroke, Ischemic Stroke
Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay.
- Conditions
- Stroke, Ischemic Stroke, Cerebral Infarction, Atrial Fibrillation
- Trial name
- SPICAF (NCT06486792)
- Testing
- Apixaban, Aspirin
- Where
- France
- Volunteers
- 1,148 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris